cover image European Journal of Neurology

European Journal of Neurology

2021 - Volume 28
Issue 1 | January 2021

Issue Information

Issue Information

Guidelines

Background and purpose

Some epilepsy syndromes (sleep‐related epilepsies, SREs) have a strong link with sleep. Comorbid sleep disorders are common in patients with SRE and can exert a negative impact on seizure control and quality of life. Our purpose was to define the standard procedures for the diagnostic pathway of patients with possible SRE (scenario 1) and the general management of patients with SRE and comorbidity with sleep disorders (scenario 2).

Methods

The project was conducted under the auspices of the European Academy of Neurology, the European Sleep Research Society and the International League Against Epilepsy Europe. The framework entailed the following phases: conception of the clinical scenarios; literature review; statements regarding the standard procedures. For the literature search a stepwise approach starting from systematic reviews to primary studies was applied. Published studies were identified from the National Library of Medicine’s MEDLINE database and Cochrane Library.

Results

Scenario 1: Despite a low quality of evidence, recommendations on anamnestic evaluation and tools for capturing the event at home or in the laboratory are provided for specific SREs. Scenario 2: Early diagnosis and treatment of sleep disorders (especially respiratory disorders) in patients with SRE are likely to be beneficial for seizure control.

Conclusions

Definitive procedures for evaluating patients with SRE are lacking. Advice is provided that could be of help for standardizing and improving the diagnostic approach of specific SREs. The importance of identifying and treating specific sleep disorders for the management and outcome of patients with SRE is underlined.

Letter to the Editor

Striatal dopaminergic denervation and hypomimia in Parkinson's disease

Letters to the Editor

Unblinded by the light: amyloid‐related imaging abnormalities in Alzheimer’s clinical trials

Original Article

Background and purpose

Mechanical thrombectomy (MT) is the standard of care for patients with anterior circulation large vessel occlusion. Early neurological improvement (ENI), defined as a reduction of ≥ 8 on the National Institutes of Health Stroke Scale (NIHSS) compared with baseline score, or an NIHSS score of 0 or 1 at 24 h after MT, is a strong predictor of 3‐month favorable outcome in such patients. The impact of ENI after MT in stroke patients with basilar artery occlusion (BAO) on 3‐month outcome is not clear. We aimed to study the effects of ENI in patients with BAO.

Methods

We performed a retrospective analysis of a multicenter prospective cohort of all consecutive stroke patients with BAO who underwent MT. We compared clinical outcomes between BAO patient groups according to ENI status. Multivariate analyses were performed to determine the impact of ENI on favorable 90‐day outcome (modified Rankin scale score 0–3) and to report factors contributing to ENI.

Results

A total of 237 patients were included. ENI was observed in 70 patients (30%). Outcomes were significantly better in ENI‐positive patients, with 84% achieving favorable outcome (mRS score 0–3) at 3 months versus 30% for ENI‐negative patients (< 0.0001). In multivariate analysis, ENI was an independent predictive factor associated with higher rates of favorable outcome {odds ratio (OR) 18.12 [95% confidence interval (CI) 3.95–83.10];  = 0.0001}. Higher number of passes [OR 0.62 (95% CI 0.43–0.89);  = 0.010] and need for stenting [OR 0.27 (95% CI 0.07–0.95);  = 0.041] were negatively associated with ENI.

Conclusion

Early neurological improvement on day 1 following MT for BAO is a strong independent predictor of a favorable 3‐month clinical outcome.

Original Article

Background and purpose

Functional movement disorders (FMDs) pose a diagnostic challenge for clinicians. Over the years several associated features have been shown to be suggestive for FMDs. Which features mentioned in the literature are discriminative between FMDs and non‐FMDs were examined in a large cohort. In addition, a preliminary prediction model distinguishing these disorders was developed based on differentiating features.

Method

Medical records of all consecutive patients who visited our hyperkinetic outpatient clinic from 2012 to 2019 were retrospectively reviewed and 12 associated features in FMDs versus non‐FMDs were compared. An independent test for age of onset and Pearson chi‐squared analyses for all categorical variables were performed. Multivariate logistic regression analysis was performed to develop a preliminary predictive model for FMDs.

Results

A total of 874 patients were eligible for inclusion, of whom 320 had an FMD and 554 a non‐FMD. Differentiating features between these groups were age of onset, sex, psychiatric history, family history, more than one motor phenotype, pain, fatigue, abrupt onset, waxing and waning over long term, and fluctuations during the day. Based on these a preliminary predictive model was computed with a discriminative value of 91%.

Discussion

Ten associated features are shown to be not only suggestive but also discriminative between hyperkinetic FMDs and non‐FMDs. Clinicians can use these features to identify patients suspected for FMDs and can subsequently alert them to test for positive symptoms at examination. Although a first preliminary model has good predictive accuracy, further validation should be performed prospectively in a multi‐center study.

Original Article

Background and Purpose

The number of clot retrieval attempts required to achieve complete reperfusion by mechanical thrombectomy impacts functional outcome in acute ischaemic stroke (AIS). Complete reperfusion [expanded Treatment In Cerebral Infarction (eTICI) score = 3] at first pass (FP), is associated with the highest rates of favorable outcome compared to complete reperfusion by multiple passes. The aim of the present study was to investigate the relationship between FP complete reperfusion and infarct growth (IG).

Methods

Anterior AIS patients with baseline and 24‐h diffusion‐weighted magnetic resonance imaging were included from two prospective registries. IG was measured by voxel‐based segmentation of initial and 24‐h diffusion‐weighted imaging lesions. IG and favorable 3‐month modified Rankin Scale (mRS) score (≤ 2) were compared between patients in whom complete reperfusion (eTICI 3) was achieved with a single pass (FP group) and those for whom multiple passes were required (MP group), after matching for confounding factors. Mediation analysis was performed to examine the association between FP and 3‐month mRS score, with IG as mediating variable.

Results

A total of 200 patients were included, of whom 118 (28.9%) had FP complete reperfusion. In case–control analysis, the FP group had lower IG than the MP group [8.7 (5.4–12.9) ml vs. 15.2 (11–22.6) ml, respectively;  = 0.03). Favorable outcome was higher in the FP population compared to a matched MP population (70.9% vs. 53.2%, respectively;  = 0.04). FP compete reperfusion (eTICI 3) was independently associated with favorable outcome in multivariable regression analysis [odds ratio 1.86, 95% confidence interval (CI) 1.01–4.39;  = 0.04]. The effect of complete reperfusion at FP on functional outcome was explained by limited IG in mediation analysis [indirect effect: −0.32 (95% CI −0.47 to −0.09)].

Conclusion

Complete reperfusion at FP is independently associated with significant decrease in IG compared to complete reperfusion by multiple attempts, explaining better functional outcomes.

Original Article

Background and purpose

Neurological manifestations in coronavirus disease (COVID)‐2019 may adversely affect clinical outcomes. Severe COVID‐19 and uremia are risk factors for neurological complications. However, the lack of insight into their pathogenesis, particularly with respect to the role of the cytokine release syndrome (CRS), is currently hampering effective therapeutic interventions. The aims of this study were to describe the neurological manifestations of patients with COVID‐19 and to gain pathophysiological insights with respect to CRS.

Methods

In this longitudinal study, we performed extensive clinical, laboratory and imaging phenotyping in five patients admitted to our renal unit.

Results

Neurological presentation included confusion, tremor, cerebellar ataxia, behavioral alterations, aphasia, pyramidal syndrome, coma, cranial nerve palsy, dysautonomia, and central hypothyroidism. Notably, neurological disturbances were accompanied by laboratory evidence of CRS. Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) was undetectable in the cerebrospinal fluid (CSF). Hyperalbuminorrachia and increased levels of the astroglial protein S100B were suggestive of blood−brain barrier (BBB) dysfunction. Brain magnetic resonance imaging findings comprised evidence of acute leukoencephalitis ( = 3, one of whom had a hemorrhagic form), cytotoxic edema mimicking ischaemic stroke ( = 1), or normal results ( = 2). Treatment with corticosteroids and/or intravenous immunoglobulins was attempted, resulting in rapid recovery from neurological disturbances in two cases. SARS‐CoV2 was undetectable in 88 of the 90 patients with COVID‐19 who underwent Reverse Transcription‐PCR testing of CSF.

Conclusions

Patients with COVID‐19 can develop neurological manifestations that share clinical, laboratory and imaging similarities with those of chimeric antigen receptor T‐cell‐related encephalopathy. The pathophysiological underpinnings appear to involve CRS, endothelial activation, BBB dysfunction, and immune‐mediated mechanisms.

Original Article

Background and purpose

Various clinical and neuroimaging predictive factors have been identified for the recovery of upper extremity (UE) motor function after stroke. However, few studies have addressed factors related to the recovery of lower extremity (LE) motor function after stroke or performed direct comparisons of UE and LE motor recovery in the same set of patients. In this study, predictive factors for UE and LE motor recovery after stroke were investigated using clinical and neuroimaging characteristics.

Methods

Forty‐two subacute ischaemic stroke patients underwent structural and functional magnetic resonance imaging data acquisition and cognitive/behavioral assessments using the Fugl–Meyer assessment, the National Institutes of Health Stroke Scale (NIHSS) and the Mini‐Mental State Examination (MMSE) 2 weeks after stroke onset. Neuroimaging factors, including corticospinal tract (CST) fractional anisotropy, lesion volume, CST lesion load and interhemispheric homotopic functional connectivity, were extracted. The outcome of motor function was assessed by Fugl–Meyer assessment scores 3 months after onset.

Results

Early clinical and neuroimaging factors for predicting motor recovery were noticeably different for UE and LE. UE motor function recovery was related to age, NIHSS, MMSE, CST lesion load, lesion volume, ipsilesional CST integrity and interhemispheric homotopic functional connectivity. In contrast, LE motor recovery was related to ipsilesional and contralesional CST integrity and MMSE. Specifically, LE recovery showed a strong relationship to the preservation of cognitive function compared with motor impairment.

Conclusions

Our results indicate that different mechanisms underlie UE and LE motor recovery after stroke. LE motor recovery seems to be more intensively modulated by cognitive functions than UE.

Original Article

Background and purpose

Few studies have assessed the role of vitamin D in the association between cardiovascular risk factors and cognitive function. Here, the aim was to investigate the association between cardiovascular health (CVH) and cognitive function according to vitamin D level in a middle‐aged Korean population.

Methods

This cross‐sectional study included 840 men and 1811 women (mean age 57.2 years) from the Cardiovascular and Metabolic Diseases Etiology Research Center study baseline enrolment (2013–2018). Life's Simple 7 tools from the American Heart Association were used to assess CVH. Cognitive function was evaluated using the Mini‐Mental State Estimation for Dementia Screening (MMSE‐DS), and the serum 25‐hydroxyvitamin D level was measured.

Results

In the adjusted generalized linear regression models, no significant association between a high Life’s Simple 7 score (4–7 metric at optimal level) and MMSE‐DS score ( = 0.01,  = 0.93) was found. Amongst men with a high vitamin D level, the high Life’s Simple 7 score group showed a significantly higher MMSE‐DS score ( = 0.48,  = 0.03). However, amongst men in the low vitamin D group, the association was opposite with no statistical significance ( = −0.23,  = 0.08). In women, the results were similar, but both strata according to vitamin D level showed no statistical significance.

Conclusions

Our findings suggest that vitamin D is an effect modifier in the association between CVH and cognition, especially in men.

Original Article

Background and purpose

Little is known about the epidemiological features of amyotrophic lateral sclerosis (ALS) in sub‐Saharan Africa, and data from the region are limited to clinical series or case reports. The aim of the study was to investigate the incidence rate and presentation of ALS in an ethnically diverse region of South Africa.

Methods

We performed a 4‐year prospective incidence study in the Western Cape Province of South Africa between 1 July 2014 and 30 June 2018, and used a two‐source capture‐recapture method for case ascertainment. Age‐ and sex‐adjusted incidence rates (ASAIRs) were calculated using the 2010 US population as the reference.

Results

A total of 203 incident cases were identified over the study period, resulting in a crude incidence rate (IR) of 1.09 [95% confidence interval (CI) 0.94–1.24] per 100 000 person‐years in the at‐risk population (aged >15 years). Capture‐recapture analysis resulted in an estimated IR of 1.11 (95% CI 1.01–1.22) per 100 000 person‐years. The ASAIR was 1.67 (95% CI 1.09–2.26) overall; 1.99 (95% CI 1.60–2.39) for men and 1.37 (95% CI 1.06–1.68) for women. When analysed separately, there was a substantial difference in ASAIRs between the different population groups, with the highest in the European ancestry group (2.62; 95% CI 2.49–2.75), the lowest in the African ancestry group (0.56, 95% CI 0.0–1.23), and an ASAIR in between these two in the mixed ancestry group (1.09, 95% CI 0.80–1.37).

Conclusion

The overall incidence of ALS in the Western Cape Province of South Africa appears to be lower than in North African and Western countries, but higher than in Asian countries. As suggested by previous epidemiological studies, ALS may be less frequent in people of African ancestry.

Original Article

Objective

To investigate changes in serum complements and their regulators in the pathogenesis of myasthenia gravis (MG).

Methods

Forty‐four patients with acetylcholine receptor antibody‐positive MG, as well as 20 patients with non‐inflammatory neurological disorders were enrolled. Serum complements (C3, C4 and soluble C5b‐9) and complement regulators (vitronectin, clusterin and properdin) were extensively analysed by enzyme‐linked immunosorbent assay and their associations with clinical profiles of MG were examined.

Results

Serum C3, C4 and clusterin levels were not significantly different between patients with MG and controls. The patients with MG had higher soluble C5b‐9 ( = 0.09) and vitronectin ( = 0.001) levels than the controls; moreover, vitronectin levels decreased after treatment ( = 0.09). Serum properdin ( = 0.03) levels were lower in the patients with MG than in the controls, and negatively correlated with the MG Activities of Daily Living score (s = −0.26,  = 0.09) and with the presence of bulbar palsy ( = 0.04).

Conclusion

Our results show that activation of complements and an altered complement network could contribute to the inflammatory pathogenesis of MG.

Original Article

Background and purpose

High peak serum immunoglobulin G (IgG) levels may not be needed for maintenance intravenous immunoglobulin (IVIg) treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and such high levels may cause side effects. More frequent lower dosing may lead to more stable IgG levels and higher trough levels, which might improve efficacy. The aim of this trial is to investigate whether high frequent low dosage IVIg treatment is more effective than low frequent high dosage IVIg treatment.

Methods

In this randomized placebo‐controlled crossover trial, we included patients with CIDP proven to be IVIg‐dependent and receiving an individually established stable dose and interval of IVIg maintenance treatment. In the control arm, patients received their individual IVIg dose and interval followed by a placebo infusion at half the interval. In the intervention arm, patients received half their individual dose at half the interval. After a wash‐out phase patients crossed over. The primary outcome measure was handgrip strength (assessed using a Martin Vigorimeter). Secondary outcome indicators were health‐related quality of life (36‐item Short‐Form Health Survey), disability (Inflammatory Rasch‐built Overall Disability Scale), fatigue (Rasch‐built Fatigue Severity Scale) and side effects.

Results

Twenty‐five patients were included and were treated at baseline with individually adjusted dosages of IVIg ranging from 20 to 80 g and intervals ranging from 14 to 35 days. Three participants did not complete the trial; the main analysis was therefore based on the 22 patients completing both treatment periods. There was no significant difference in handgrip strength change from baseline between the two treatment regimens (coefficient −2.71, 95% CI −5.4, 0.01). Furthermore, there were no significant differences in any of the secondary outcomes or side effects.

Conclusions

More frequent lower dosing does not further improve the efficacy of IVIg in stable IVIg‐dependent CIDP and does not result in fewer side effects.

Original Article

Background and purpose

Whole‐body muscle magnetic resonance imaging (MRI) has become widely used for diagnostic workup in patients with muscle diseases. The prevalence of incidental findings in diagnostic whole‐body muscle MRI is unknown. Here, the prevalence and outcomes of incidentalomas in whole‐body muscle MRI in a large cohort of patients with muscle symptoms were studied.

Methods

Two hundred and six patients who consulted at our neuromuscular clinic with muscle weakness and/or myalgia and/or increased serum creatine kinase and in whom a whole‐body muscle MRI was performed between January 2016 and March 2020 were included.

Results

Whole‐body muscle MRI revealed at least one incidentaloma in 132 patients (64.1%), with mean age at MRI examination 50.4 years (19–74 years). Most of the incidental findings were benign. However, diagnostic examinations were indicated in 16.3% of the incidentalomas, treatment was needed in 4.7% and, in retrospect, symptoms related to the incidental findings were identified in 14.3%. Three malignant (glioblastoma multiforme, renal cell carcinoma and hepato‐splenomegaly related to a lymphoma) and one precancerous (low‐grade appendiceal mucinous neoplasm) incidental findings were identified. In one patient an abdominal aortic aneurysm was detected and in another a large cerebral arteriovenous malformation. In 1.2% of the incidentalomas, i.e. periventricular white matter lesions ( mutations) and fibrous dysplasia ( mutations), an indirect link with the muscle disease could be established.

Conclusions

It is concluded that incidental findings in diagnostic whole‐body muscle MRI in patients with muscle symptoms occur frequently. Most of them are benign, but in some timely detecting the incidentaloma leads to early treatment and can thus impact prognosis.

Letter To The Editor

Effects of COVID‐19 outbreak on stroke admissions in Brescia, Lombardy, Italy

Original Article

Background and purpose

Anxiety and depression are common disabling comorbidities in cervical dystonia (CD) and may predispose to social withdrawal and social cognitive impairments. The relationship between social cognition and depressive/anxiety symptoms in CD is under‐investigated.

Methods

Forty‐six CD patients (40 women; mean age ± SD, 55.57 ± 10.84 years) were administered the following social cognition battery: Affect Naming, Prosody Face and Pair Matching subtests from the Wechsler Adult Intelligence Scale IV and Wechsler Memory Scale IV (social perception), reality‐known and reality‐unknown false belief reasoning tasks (theory of mind), Empathy Quotient and Social Norms Questionnaire 22 (social behaviour), alongside the Benton Facial Recognition Task (non‐emotional facial discrimination). Alongside CD severity, the Hospital Anxiety and Depression Scale measured depressive/anxiety comorbid diagnostic status and severity, and the Liebowitz Social Anxiety Scale assessed social phobia. Social cognition tasks were standardized using published normative data and a cut‐off of  < −1.5 for impairment.

Results

More than 90% of our CD patients performed normally on social perception and social behaviour tests. Performance on impaired belief reasoning (theory of mind) was impaired in 10 of 46 (21.74%); five of 46 (10.87%) were impaired on the Empathy Quotient. Better performance on the Affect Naming task was associated with comorbid anxiety ( = 0.09, medium‐to‐large effect size) and greater anxiety, depression and social phobia severity. Worse performance on the Empathy Quotient was associated with comorbid depression ( = 0.11, medium‐to‐large effect size) and greater depression severity. CD patients had significantly more difficulties with fearful face identification (< 0.001).

Conclusions

Greater social perception abilities in CD patients with more severe anxiety and depression suggest efficient modulation and self‐adaptation of social cognitive skills.

Original Article

Background and purpose

Intravenous thrombolysis plus mechanical thrombectomy (IVT + MT) is the best current management of acute stroke due to large‐vessel occlusion and results in optimal reperfusion for most patients. Nevertheless, some of these patients do not subsequently achieve functional independence. The aim was to identify baseline factors associated with 3‐month independence after optimal reperfusion and to validate a prediction model.

Methods

All consecutive patients with intracranial anterior large‐vessel occlusion, with indication for IVT + MT and achieving optimal reperfusion (defined as modified Treatment in Cerebral Ischaemia score 2b–3), from the THRACE trial and the ETIS registry, were included in order to identify a prediction model. The primary outcome was 3‐month independence [modified Rankin Scale (mRS) score ≤ 2]. Multivariate inferences invoked forward logistic regression, multiple imputation and bootstrap resampling. Predictive performance was assessed by ‐statistic. Model validation was conducted on patients from the ASTER trial.

Results

Amongst 139 patients (mean age 65.5 years; 54.3% female), predictors of 3‐month mRS ≤ 2 ( = 82) were younger age [odds ratio 0.62 per 10‐year increase; 95% confidence interval (CI) 0.53–0.72] and higher Alberta Stroke Program Early Computed Tomography Score (ASPECTS) (odds ratio 1.65 per 1‐point increase; 95% CI 1.47–1.86) with ‐statistic 0.77. Model validation ( = 104/181 patients with 3‐month mRS ≤ 2) demonstrated a moderate discrimination (‐statistic 0.74; 95% CI 0.66–0.81) combining age and ASPECTS. The validation model was improved by the adjunction of three candidate variables that were found to be predictors. Addition of baseline National Institutes of Health Stroke Scale (NIHSS) score, history of vascular risk factor and onset‐to‐reperfusion time significantly improved discrimination (‐statistic 0.85; 95% CI 0.83–0.87).

Conclusions

After optimal reperfusion, younger age, higher ASPECTS, lower NIHSS score, shorter onset‐to‐reperfusion time and absence of vascular risk factor were predictive of independence and could help to guide patient management.

Original Article

Background and purpose

Early neurological improvement (ENI) after endovascular thrombectomy (EVT) has been associated with favorable outcomes. This study aimed to identify the optimal definition of ENI and develop a nomogram for predicting ENI after EVT in acute ischaemic stroke.

Methods

Patients with EVT were enrolled from a multicenter registry as the training cohort. The receiver operating characteristic curve was used to estimate the optimal threshold for ENI at 24 h of EVT. Logistic regression analysis was utilized to generate the best‐fit nomogram for predicting ENI. The discrimination of the nomogram was assessed using the area under the receiver operating characteristic curve (AUC). An additional 447 patients from two stroke centers were prospectively recruited as the test cohort for validating the nomogram.

Results

A total of 612 patients with EVT were included in the training cohort. The optimal threshold for predicting 3‐month favorable outcome (modified Rankin Scale 0–2) was an improvement of the National Institutes of Health Stroke Scale (NIHSS) score by ≥6 points (AUC 0.875; sensitivity 79.5%; specificity 90.7%). Age, blood glucose, recanalization, symptomatic intracranial hemorrhage (sICH) and baseline Alberta Stroke Program Early Computed Tomography Score (ASPECTS) were independently associated with ENI, and were incorporated in the nomogram. The AUC of the nomogram was 0.795 in the training cohort and 0.752 in the test cohort.

Conclusions

A reduction of NIHSS score ≥6 appeared to be the optimal definition of ENI. The nomogram composed of age, blood glucose, recanalization, sICH and baseline ASPECTS may predict the probability of ENI in ischaemic stroke patients treated with EVT.

Original Article

Background and purpose

The burden of cervical arterial atherosclerosis, which is an important risk factor of stroke, is huge in China. The visceral adiposity index (VAI) is a convenient index that is related to a series of metabolic abnormalities and a variety of diseases, including cerebrovascular diseases. This study aimed to explore the relationship between VAI and cervical arterial atherosclerosis.

Methods

This cross‐sectional study used the multistage stratified random cluster sampling method to acquire a representative sample of residents aged ≥40 in the general population of northeast China. All participants completed a detailed questionnaire and provided blood samples. Cervical vascular ultrasound was performed by experienced ultrasound doctors. VAI was calculated by a well‐established formula and analyzed by quartiles (Q1–Q4).

Results

A total of 3688 people aged ≥40 years who underwent cervical arterial ultrasound were finally included, amongst whom 3.2% had increased intima‐media thickness (IMT), 48.6% had carotid plaque and 4.0% had cervical artery stenosis (CAS). After adjusting for several parameters, little statistical significance was found between VAI and increased IMT; compared with the VAI‐Q1 group, the VAI‐Q2, VAI‐Q3 and VAI‐Q4 groups were more likely to have CAS [odds ratio (OR) 2.01, 95% confidence interval (CI) 1.17–3.43; OR 1.82, 95% CI 1.05–3.15; OR 1.79, 95% CI 1.03–3.12] and the VAI‐Q3 and VAI‐Q4 groups were at greater risk of carotid plaque (OR 1.30, 95% CI 1.05–1.62; OR 1.34, 95% CI 1.07–1.67).

Conclusions

The VAI was related to carotid plaque and CAS in the general population that is older than 40 years.

Original Article

Background and purpose

In a subset of patients with inherited peripheral neuropathies the first symptom is atrophy and weakness of the intrinsic muscles of the hands, without involvement of lower limbs until later in the disease course. The exact pathomechanisms of this phenotype are currently unknown. The aim of this study was to characterize the clinical, neurophysiological and genetic features of a group of patients with a clinical diagnosis of upper limb predominant Charcot‐Marie‐Tooth disease (CMT).

Methods

The clinical, electrophysiology and genetic data of 11 patients with upper limb predominant peripheral neuropathy selected from a single‐centre cohort of 461 patients diagnosed with inherited neuropathy were analysed and the clinical, electrophysiological and genetic characteristics of these patients reported.

Results

An overlapping phenotype of neuropathy and myopathy was detected in two patients. Four patients carry autosomal dominant mutations in and a single patient had a homozygous mutation in . However, the underlying genetic diagnosis could not be confirmed in six patients by gene panel sequencing.

Conclusions

Upper limb‐onset inherited neuropathies are genetically heterogeneous and, in some cases, there is an overlapping myopathy. Autosomal dominant mutations are the most common genetic cause; however, mutations in other CMT genes may also result in this phenotype in individual patients. The majority of these patients cannot be genetically diagnosed by gene panel testing of known CMT and myopathy genes, suggesting further genetic heterogeneity and highlighting the importance of further genetic investigations in these patients and families.

Original Article

Background and purpose

In amyotrophic lateral sclerosis, studies using threshold‐tracking transcranial magnetic stimulation (TMS) have identified corticomotoneuronal dysfunction as a key pathogenic mechanism. Some patients, however, display no motor response at maximal TMS intensities, termed here an ‘inexcitable’ motor cortex. The extent to which this cortical difference impacts clinical outcomes remains unclear. The aim of this study was to determine the clinical profile of patients with inexcitability to TMS.

Methods

Motor cortex excitability was evaluated using TMS. Patients in whom a motor evoked potential could not be recorded in one or more limbs at maximal TMS intensities were classified as four‐limb or partially inexcitable. Demographic information, clinical variables and survival data were analysed.

Results

From 133 patients, 40 were identified with inexcitability. Patients with four‐limb inexcitability were younger ( = 0.03) and had lower‐limb disease onset (64%), greater functional disability ( < 0.001) and faster disease progression ( = 0.02), particularly if inexcitability developed within 1 year of symptoms ( < 0.01). Patients with partial inexcitability had higher resting motor thresholds compared to the excitable cohort ( < 0.01), but averaged short‐interval intracortical inhibition was similar ( = 0.5). Mean survival was reduced if inexcitability involved all limbs within 12 months of symptom onset ( = 0.04).

Conclusion

Amyotrophic lateral sclerosis patients with inexcitability of all four limbs to TMS have a distinct clinical profile of younger age and lower‐limb onset. Importantly, these patients display a more malignant disease trajectory, with faster progression, greater functional disability and reduced survival when occurring in early disease. This measure may provide an important prognostic marker in amyotrophic lateral sclerosis.

Original Article

Background and purpose

Dysphagia is common in acute stroke and leads to worse overall outcome. Transesophageal echocardiography (TEE) is used in the diagnostic evaluation of stroke with regard to its etiology and is a known cause of postoperative dysphagia in cardiac surgery. The prevalence of dysphagia in acute stroke patients undergoing TEE remains unknown. The aim of the Transesophageal Echocardiography – Dysphagia Risk in Acute Stroke (TEDRAS) study was to assess the influence of TEE on swallowing among patients who have experienced acute stroke.

Methods

The TEDRAS study was a prospective, blind, randomized, controlled trial that included two groups of patients with acute stroke. Simple unrestricted randomization was performed, and examiners were blinded to each other's results. Swallowing was tested using flexible endoscopic evaluation of swallowing (FEES) at three different time points in the intervention group (24 h before, immediately after and 24 h after TEE) and in the control group (FEES on three consecutive days and TEE earliest after the third FEES). Validated scales were used to assess dysphagia severity for all time points as primary outcome measures.

Results

A total of 34 patients were randomized: 19 to the intervention group and 15 to the control group. The key findings of the repeated‐measures between‐group comparisons were significant increases in the intervention group for the following dysphagia measures: (1) secretion severity score (immediately after TEE:  < 0.001; 24 h after TEE:  < 0.001) and (2) Penetration‐Aspiration Scale score for saliva (immediately after TEE:  < 0.001; 24 h after TEE:  = 0.007), for small (immediately after TEE:  = 0.009) and large liquid boli (immediately after TEE:  = 0.009; 24 h after TEE:  = 0.025).

Conclusion

The results indicate a negative influence of TEE on swallowing in acute stroke patients for at least 24 hours.

Original Article

Background and purpose

Stroke is the second largest single cause of death in Europe, responsible for 9% and 13% of all deaths in men and women, respectively. There have been large overall declines in stroke mortality rates in the majority of European countries in recent decades. The aim of this study was to analyse trends in mortality caused by stroke in the 28 member countries of the European Union (EU) over the last two decades.

Methods

We extracted data for age‐standardized stroke mortality rates per 100 000 in the EU for the period 1996–2015 from the World Health Organization database. Joinpoint regression analysis was used to analyse the trends and compute the annual percent change (APC) in the EU as a whole and by country. Analyses were conducted by gender and by European region.

Results

Mortality from stroke has decreased in the EU over the study period by an average APC of 4.2%. All countries showed downward trends, with the sharpest decreases in Estonia, Portugal and Austria. We recorded statistically significant decreases of 4.2% and 4.3% in mortality rates in men and women, respectively, in the whole EU. Southern and western countries showed the steepest decreases, whereas mortality has increased in northern countries in recent years.

Conclusions

Stroke mortality has decreased in the EU, in both sexes, especially in southern and western European countries. Our results could be a reference for the development of primary prevention and acute management of stroke policies focused on countries with higher mortality.

Original Article

Background and purpose

and genes have been implicated in sleep–wake cycle alterations and neurodegenerative diseases. Our aim was to evaluate the effect of T3111C and C111G on cognitive functioning in subjective cognitive decline (SCD) patients and mild cognitive impairment (MCI) patients at the baseline of a longitudinal study, and the effect of these two polymorphisms on the progression to Alzheimer’s disease (AD) of the two groups.

Methods

Sixty‐eight subjects (41 SCD and 27 MCI) who underwent clinical evaluation, neuropsychological assessment, and genotyping at baseline and neuropsychological follow‐up every 2 years for a mean time of 10 years were included. Subjects who developed AD (SCD‐c and MCI‐c) and non‐converters (SCD‐nc, MCI‐nc) were considered.

Results

T3111C was detected in 47% of cases (21 SCD, 11 MCI) and C111G in 19% of cases (eight SCD and five MCI). G carriers presented lower premorbid intelligence score ( = 0.049), fewer years of education ( = 0.007) and a lower frequency of family history of AD ( = 0.04) than G non‐carriers. MCI G carriers had worse performance in tests assessing memory, executive function, language and visuospatial abilities at baseline. During follow‐up, two SCD and 15 MCI subjects progressed to AD: both of the SCD‐c subjects presented the G allele, while none of the SCD G non‐carriers converted to AD ( = 0.003).

Conclusion

seems to have a role in cognitive reserve and cognition in SCD and MCI patients. Nevertheless, further studies are needed to assess the role of C111G on the risk of progression to AD.

Original Article

Background and purpose

Although highly disabling, the pathogenesis and evolution of fatigue in Parkinson’s disease (PD) is largely unknown, and no sufficiently documented treatment currently exists. The aim of the present study was to investigate the evolution of fatigue during the first 9 years after diagnosis.

Methods

This study is part of the Norwegian ParkWest collaboration, a prospective population‐based longitudinal cohort study. The present study comprised 191 newly diagnosed patients and 170 control participants. Fatigue was assessed by the Fatigue Severity Scale, with examinations at baseline and then every other year up to 9 years of follow‐up. Linear mixed models were applied to investigate possible variables associated with fatigue.

Results

It was found that there was a statistically significant increase in the proportion of PD patients with fatigue during the first 9 years after diagnosis. A large proportion of patients had a significant increase or decrease in fatigue score between consecutive visits. In addition, the relative risk of persistent fatigue and ever having fatigue was higher than for controls. There were statistically significant longitudinal associations between higher levels of fatigue and female gender, comorbidity at baseline, depressive symptoms, dependency in activities of daily living and better cognitive functioning. Lower levels of fatigue were associated with the use of dopamine agonists.

Conclusion

Fatigue is a common, severely limiting symptom in PD. This study demonstrates associations with other factors that could yield a better understanding of the symptom and thus possible treatment strategies, although further investigations are necessary to establish causal relationships.

Guidelines

Background and purpose

The recent SARS‐CoV‐2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast‐evolving pandemic, evidence‐based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID‐19.

Methods

A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP co‐chairs rated importance on a five‐point Likert scale. Results were graded by importance and reported as consensus statements.

Results

In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fifty‐nine statements obtained >70% agreement and were retained. In round three, responses were received from 55 co‐chairs of 29 SPs. Whilst general recommendations related to prevention of COVID‐19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy.

Conclusion

This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVID‐19 pandemic that provides immediate guidance for neurologists. In this fast‐evolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges.

Original Article

Background and objectives

The ability to perform instrumental activities of daily living (IADL) is important for maintaining independent living, and optimal health‐related quality of life and well‐being. Neuropsychological measures are predictors of IADL ratings. The aims of the present study were to measure ability to perform IADL in patients with cancer and to explore the relationship between IADL and neuropsychological functioning.

Methods

We evaluated IADL in 182 patients with four different types of cancer (thyroid, colorectal, breast and prostate cancer) and examined the relationship between IADL and neuropsychological functioning 6 months after chemotherapy treatment.

Results

Our results showed that patients with breast cancer had significantly greater difficulty in performing IADL compared to patients with other types of cancer. There were no differences in IADL performance among the other three study groups. In addition, we found that neuropsychological score was a predictor of IADL; the greater the patients' disability, the lower their performance on neuropsychological measures. This is in accordance with the literature that suggests neuropsychological measures to be predictors of IADL ratings.

Conclusions

The present findings are important because, although many researchers have studied the relationship between IADL and neuropsychological functioning in cancer, few studies have investigated IADL in different types of cancer. Optimal neuropsychological functioning is connected with better ability with regard to IADL.

Original Article

Background and purpose

Objective measurement of speech has shown promising results to monitor disease state in multiple sclerosis. In this study, we characterize the relationship between disease severity and speech metrics through perceptual (listener based) and objective acoustic analysis. We further look at deviations of acoustic metrics in people with no perceivable dysarthria.

Methods

Correlations and regression were calculated between speech measurements and disability scores, brain volume, lesion load and quality of life. Speech measurements were further compared between three subgroups of increasing overall neurological disability: mild (as rated by the Expanded Disability Status Scale ≤2.5), moderate (≥3 and ≤5.5) and severe (≥6).

Results

Clinical speech impairment occurred majorly in people with severe disability. An experimental acoustic composite score differentiated mild from moderate ( < 0.001) and moderate from severe subgroups ( = 0.003), and correlated with overall neurological disability ( = 0.6,  < 0.001), quality of life ( = 0.5,  < 0.001), white matter volume ( = 0.3,  = 0.007) and lesion load ( = 0.3,  = 0.008). Acoustic metrics also correlated with disability scores in people with no perceivable dysarthria.

Conclusions

Acoustic analysis offers a valuable insight into the development of speech impairment in multiple sclerosis. These results highlight the potential of automated analysis of speech to assist in monitoring disease progression and treatment response.

Original Article

Background and purpose

Hierarchical clustering, a common ‘unsupervised’ machine‐learning algorithm, is advantageous for exploring potential underlying aetiology in particularly heterogeneous diseases. We investigated potential embolic sources in embolic stroke of undetermined source (ESUS) using a data‐driven machine‐learning method, and explored variation in stroke recurrence between clusters.

Methods

We used a hierarchical k‐means clustering algorithm on patients’ baseline data, which assigned each individual into a unique clustering group, using a minimum‐variance method to calculate the similarity between ESUS patients based on all baseline features. Potential embolic sources were categorised into atrial cardiopathy, atrial fibrillation, arterial disease, left ventricular disease, cardiac valvulopathy, patent foramen ovale (PFO) and cancer.

Results

Among 800 consecutive ESUS patients (43.3% women, median age 67 years), the optimal number of clusters was four. Left ventricular disease was most prevalent in cluster 1 (present in all patients) and perfectly associated with cluster 1. PFO was most prevalent in cluster 2 (38.9% of patients) and associated significantly with increased likelihood of cluster 2 [adjusted odds ratio: 2.69, 95% confidence interval (CI): 1.64–4.41]. Arterial disease was most prevalent in cluster 3 (57.7%) and associated with increased likelihood of cluster 3 (adjusted odds ratio: 2.21, 95% CI: 1.43–3.13). Atrial cardiopathy was most prevalent in cluster 4 (100%) and perfectly associated with cluster 4. Cluster 3 was the largest cluster involving 53.7% of patients. Atrial fibrillation was not significantly associated with any cluster.

Conclusions

This data‐driven machine‐learning analysis identified four clusters of ESUS that were strongly associated with arterial disease, atrial cardiopathy, PFO and left ventricular disease, respectively. More than half of the patients were assigned to the cluster associated with arterial disease.

Original Article

Background and purpose

Functional neurological disorder (FND) is a common diagnosis within neurology. Effective communication of the diagnosis is known to be an important part of treatment and can result in reduction or cessation of symptoms, as well as decreased healthcare utilisation. A single group education session, facilitated by professionals commonly involved in the care of patients with FND, was developed to further enhance patients' and relatives' understanding and acceptance of diagnosis.

Methods

Patients and relatives attending a single education session were asked to complete self‐report ratings of understanding of diagnosis, acceptance of diagnosis, belief in treatability and hopefulness regarding recovery, at the beginning and end of the session. Satisfaction data were also collected.

Results

Data were obtained from 193 patients and 153 relatives. Patients had experienced a median duration of symptoms of 4 years, and more than 80% of patients reported more than one functional neurological symptom. There were significant increases in terms of understanding, acceptance, belief in treatability and hopefulness for patients and relatives. Effect sizes ranged from large for improved understanding of FND to small‐to‐medium for increased agreement with FND diagnosis. High levels of satisfaction were also reported.

Conclusions

A multidisciplinary, single group education session is an effective and acceptable method of increasing understanding and acceptance of an FND diagnosis, even for patients with a long duration of symptoms and high symptom burden. It could help improve readiness for further treatment.

Original Article

Background and purpose

Experimental studies suggest inflammation can contribute to blood barrier disruption and brain injury in cerebral venous thrombosis (CVT). We aimed to determine whether blood biomarkers of inflammation were associated with the evolution of brain lesions, persistent venous occlusion or functional outcome in patients with CVT.

Methods

Pathophysiology of Venous Infarction—Prediction of Infarction and Recanalization in CVT (PRIORITy‐CVT) was a multicenter prospective cohort study of patients with newly diagnosed CVT. Evaluation of neutrophil‐to‐lymphocyte ratio (NLR) and C‐reactive protein (CRP) concentrations in peripheral blood samples was performed at admission in 62 patients. Additional quantification of interleukin (IL)‐6 was performed at day 1, 3 and 8 in 35 patients and 22 healthy controls. Standardized magnetic resonance imaging was performed at day 1, 8 and 90. Primary outcomes were early evolution of brain lesion, early recanalization and functional outcome at 90 days.

Results

Interleukin‐6 levels were increased in patients with CVT with a peak at baseline. IL‐6, NLR and CRP levels were not related with brain lesion outcomes or early recanalization but had a significant association with unfavourable functional outcome at 90 days (IL‐6: OR = 1.28, 95% CI: 1.05–1.56,  = 0.046; NLR: OR = 1.39, 95% CI: 1.4–1.87,  = 0.014; CRP: OR = 1.756, 95% CI: 1.010–3.051,  = 0.029). Baseline IL‐6 had the best discriminative capacity, with an area under the receiver operating characteristic curve to predict unfavourable functional outcome of 0.74 ( = 0.031).

Conclusions

Increased baseline levels of NLR, CRP and IL‐6 may serve as new predictive markers of worse functional prognosis at 90 days in patients with CVT. No association was found between inflammatory markers and early evolution of brain lesion or venous recanalization.

Original Article

Background and purpose

To improve diagnoses of primary brain tumours, knowledge about early indicators is needed. Nationwide Danish health registries were used to conduct a population‐based case–control study including all persons diagnosed with a primary brain tumour between 2005 and 2014 in Denmark.

Methods

All 5135 adults diagnosed with a primary brain tumour in the Danish Cancer Registry were matched to 19 572 general population comparisons from the Danish Civil Registration System. Conditional logistic regression analyses were applied to estimate age‐ and multivariable‐adjusted odds ratios (ORs) for the occurrence of a primary brain tumour up to 10 years after hospital diagnoses or prescription of medications related to nervous system diseases and mental and behavioural disorders.

Results

Increased odds for primary brain tumour after nervous system diseases and mental and behavioural disorders manifested up to 10 years before tumour diagnosis were found. Increased odds were seen especially for hospital contacts for inflammatory nervous system diseases [OR 11.3; 95% confidence interval (CI) 6.5–19.7], epilepsy (OR 9.0; 95% CI 7.6–10.7) and antiepileptic medications (OR 3.6; 95% CI 3.2–4.0), whilst antidementia medications provided a strong, protective association for primary brain tumours (OR 0.5; 95% CI 0.3–0.8).

Conclusions

Sub‐groups of patients diagnosed with or being prescribed certain medications targeting nervous system diseases and mental and behavioural disorders may be at increased risk of being diagnosed with a primary brain tumour. Further studies should disentangle the potential underlying common pathogenetic pathways. The results are important for the development of systematic clinical approaches to ensure early diagnosis of primary brain tumours.

Original Article

Background and purpose

We quantified peripheral nerve lesions in adults with 5q‐linked spinal muscular atrophy (SMA) type 3 by analysing the magnetization transfer ratio (MTR) of the sciatic nerve, and tested its potential as a novel biomarker for macromolecular changes.

Methods

Eighteen adults with SMA 3 (50% SMA 3a, 50% SMA 3b) and 18 age‐/sex‐matched healthy controls prospectively underwent magnetization transfer contrast imaging in a 3‐Tesla magnetic resonance scanner. Two axial three‐dimensional gradient echo sequences, with and without an off‐resonance saturation rapid frequency pulse, were performed at the right distal thigh. Sciatic nerve regions of interest were manually traced on 10 consecutive axial slices in the images generated without off‐resonance saturation, and then transferred to corresponding slices generated by the sequence with the off‐resonance saturation pulse. Subsequently, MTR and cross‐sectional areas (CSAs) of the sciatic nerve were analysed. In addition, detailed neurologic, physiotherapeutic and electrophysiologic examinations were conducted in all patients.

Results

Sciatic nerve MTR and CSA reliably differentiated between healthy controls and SMA 3, 3a or 3b. MTR was lower in the SMA 3 ( < 0.0001), SMA 3a ( < 0.0001) and SMA 3b groups ( = 0.0020) than in respective controls. In patients with SMA 3, MTR correlated with all clinical scores, and arm nerve compound motor action potentials (CMAPs). CSA was lower in the SMA 3 ( < 0.0001), SMA 3a ( < 0.0001) and SMA 3b groups ( = 0.0006) than in controls, but did not correlate with clinical scores or electrophysiologic results.

Conclusions

Magnetization transfer ratio is a novel imaging marker that quantifies macromolecular nerve changes in SMA 3, and positively correlates with clinical scores and CMAPs.

Original Article

Background and purpose

The aim was to assess functional and radiological outcomes after bridging therapy (intravenous thrombolysis plus mechanical thrombectomy) versus direct mechanical thrombectomy (MT) in unknown onset stroke patients.

Methods

A cohort study was conducted on prospectively collected data from unknown onset stroke patients who received endovascular procedures at ≤6 h from symptom recognition or awakening time.

Results

Of the 349 patients with a 10‐point Alberta Stroke Program Early Computed Tomography Score (ASPECTS), 248 received bridging and 101 received direct MT. Of the 134 patients with 6–9‐point ASPECTS, 123 received bridging and 111 received direct MT. Each patient treated with bridging was propensity score matched with a patient treated with direct MT for age, sex, study period, pre‐stroke disability, stroke severity, type of stroke onset, symptom recognition to groin time (or awakening to groin time), ASPECTS and procedure time. In the two matched groups with 10‐point ASPECTS ( = 73 vs.  = 73), bridging was associated with higher rates of excellent outcome (46.6% vs. 28.8%; odds ratio 2.302, 95% confidence interval 1.010–5.244) and successful recanalization (83.6% vs. 63%; odds ratio 3.028, 95% confidence interval 1.369–6.693) compared with direct MT; no significant association was found between bridging and direct MT with regard to rate of symptomatic intracerebral hemorrhage (0% vs. 1.4%). In the two matched groups with 6–9‐point ASPECTS ( = 45 vs.  = 45), no significant associations were found between bridging and direct MT with regard to rates of excellent functional outcome (44.4% vs. 31.1%), successful recanalization (73.3% vs. 76.5%) and symptomatic intracerebral hemorrhage (0% vs. 0%).

Conclusions

Bridging at ≤ 6 h of symptom recognition or awakening time was associated with better functional and radiological outcomes in unknown onset stroke patients with 10‐point ASPECTS.

Original Article

Background and purpose

Most evidence for the association between ideal vascular health (IVH) and cognitive performance comes from high income countries. The aim was to investigate this association in the Brazilian Longitudinal Study of Adult Health.

Methods

Cognition was assessed using the word list, verbal fluency and trail making tests. The IVH score included ideal metrics for body mass index, smoking, physical activity, diet, blood pressure, fasting glucose and total cholesterol. Poor, intermediate and optimal health were characterized in those presenting 0–2, 3–4, 5–7 ideal metrics, respectively. To determine the association between IVH score and cognitive performance, linear regression models adjusted for age, sex, education, race, alcohol use, depression and thyroid function were used.

Results

In 12 271 participants, the mean age was 51.3 ± 8.9 years, 54% were women, 57% White and 53% had poor vascular health. Participants with intermediate ( = 0.064, 95% confidence interval 0.033; 0.096) and optimal health ( = 0.108, 95% confidence interval 0.052; 0.164) had better global cognitive ‐scores. In addition, interactions of IVH score with age, education and race were found, suggesting a better cognitive performance with higher IVH in older adults, Black/Brown participants and those with lower levels of education.

Conclusion

Ideal vascular health was associated with better cognitive performance. Older, Black/Brown and low‐educated participants had better cognition in the presence of higher IVH scores.

Case Study

Background and purpose

Early and accurate diagnosis is vital in cerebral nocardiosis, a very rare and infectious disease associated with a high mortality rate. Herein, we report a case that a patient with brain abscess was swiftly diagnosed and successfully treated.

Methods

We report a case of a 61‐year‐old woman with a brain abscess caused by , diagnosed by a combination of Ziehl‐Neelsen staining and metagenomics next‐generation sequencing (mNGS).

Results

A 61‐year‐old woman with left breast cancer resection, diabetes mellitus and a 7‐month discontinuous cough and fever was admitted to our hospital. On the third day of hospitalization, she experienced a sudden loss of consciousness and was diagnosed with a brain abscess and a pathological change in cerebral mass on brain magnetic resonance imaging (MRI). Due to the failure of culturing any microorganisms from the pup, the dissected sample from the patient with Ziehl‐Neelsen staining tested positive for acid‐fast bacilli and was subjected to mNGS. The pathogen was identified as and the patient was treated accordingly with linezolid and trimethoprim‐sulfamethoxazole until complete recovery was confirmed by the follow‐up cerebral MRI.

Conclusions

This is the first case report of a brain abscess caused by being swiftly diagnosed by a combination of Ziehl‐Neelsen staining and mNGS. This rapid diagnosis allowed us to successfully treat this rare infection.

Original Article

Background and purpose

Mutations in the gene cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a cerebral small vessel disease manifesting with stroke, migraine and dementia in adults. The disease displays significant phenotypic variability that is incompletely explained. Early abnormalities in vascular function have been shown in animal models. We postulated that studying changes in vascular function may offer insights into disease progression.

Methods

Twenty‐two subjects with CADASIL [50% female, 50 (±11) years] from 19 pedigrees were included in a longitudinal multimodality study using brain magnetic resonance imaging (MRI), clinical measures, neuropsychology and measures of peripheral vascular function. MRI studies included measurement of structural brain changes, cerebral blood flow (CBF) and cerebrovascular reactivity by arterial spin labelling and a CO respiratory challenge.

Results

Over 2 years, new stroke or transient ischaemic attack (TIA) occurred in five (23%) subjects and new significant disability in one (5%). There were significant increases in number of lacunes, subcortical hyperintensity volume and microbleeds, and a decrease in brain volume. CBF declined by 3.2 (±4.5) ml/100 g/min over 2 years. CBF and carotid–femoral pulse wave velocity at baseline predicted change in subcortical hyperintensity volume at follow‐up. Carotid intima‐media thickness and age predicted brain atrophy. Baseline CBF was lower in subjects who showed a decline in attention and working memory.

Conclusions

Cerebral blood flow predicts radiological progression of hyperintensities and thus is a potential biomarker of disease progression in CADASIL. Over 2 years, there were changes in several relevant imaging biomarkers (CBF, brain volume, lacunes, microbleeds and hyperintensity volume). Future studies in CADASIL should consider assessment of CBF as prognostic factor.

Original Article

Background and purpose

Recent observations linked coronavirus disease 2019 (COVID‐19) to thromboembolic complications possibly mediated by increased blood coagulability and inflammatory endothelial impairment. We aimed to define the risk of acute stroke in patients with severe and non‐severe COVID‐19.

Methods

We performed an observational, multicenter cohort study in four participating hospitals in Saxony, Germany to characterize consecutive patients with laboratory‐confirmed COVID‐19 who experienced acute stroke during hospitalization. Furthermore, we conducted a systematic review using PubMed/MEDLINE, Embase, Cochrane Library and bibliographies of identified papers following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines including data from observational studies of acute stroke in COVID‐19 patients. Data were extracted by two independent reviewers and pooled with multicenter data to calculate risk ratios (RRs) and 95% confidence intervals (95% CIs) for acute stroke related to COVID‐19 severity using a random‐effects model. Between‐study heterogeneity was assessed using Cochran’s and statistics. International Prospective Register of Systematic Reviews registration number: CRD42020187194.

Results

Of 165 patients hospitalized for COVID‐19 (49.1% males, median age = 67 years [57–79 years], 72.1% severe or critical) included in the multicenter study, overall stroke rate was 4.2% (95% CI: 1.9–8.7). Systematic literature search identified two observational studies involving 576 patients that were eligible for meta‐analysis. Amongst 741 pooled COVID‐19 patients, overall stroke rate was 2.9% (95% CI: 1.9–4.5). Risk of acute stroke was increased for patients with severe compared to non‐severe COVID‐19 (RR = 4.18, 95% CI: 1.7–10.25;  = 0.002) with no evidence of heterogeneity ( = 0%,  = 0.82).

Conclusions

Synthesized analysis of data from our multicenter study and previously published cohorts indicates that severity of COVID‐19 is associated with an increased risk of acute stroke.

Letters To The Editor

Olfactory bulb and mucosa abnormalities in persistent COVID‐19‐induced anosmia: a magnetic resonance imaging study

Original Article

Background and purpose

Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately 30% in relapsing–remitting multiple sclerosis (RRMS) patients. The relationship between this reduction and DMF effectiveness is controversial. The objective was to investigate if the decrease in absolute lymphocyte count (ALC) from baseline during DMF treatment is associated with clinical and magnetic resonance imaging (MRI) disease activity. A secondary aim was to evaluate ALC variations over time in a real‐life cohort of DMF‐treated patients.

Methods

Demographic, laboratory, clinical and MRI data were collected in this observational multicentre study, conducted on RRMS patients treated with DMF for at least 6 months. Multivariate Cox models were performed to evaluate the impact of 6‐month ALC drop on time to no evidence of disease activity (NEDA‐3) status loss. NEDA‐3 is defined as absence of clinical relapses, MRI disease activity and confirmed disability progression.

Results

In all, 476 patients (312 females, age at DMF start 38.4 ± 9.97 years) were analysed up to 5‐year follow‐up. A greater lymphocyte decrease was associated with a lower risk of NEDA‐3 status loss (hazard ratio 0.87,  = 0.01). A worse outcome in patients with lower ALC drop (<11.5%), compared with higher tertiles (11.5%–40.5% and >40.5%), was observed ( = 0.008). The nadir of ALC drop (−33.6%) and 35% of grade III lymphopaenia cases occurred after 12 months of treatment.

Conclusion

A higher lymphocyte count drop at 6 months is related to better outcomes in DMF‐treated patients. A careful ALC monitoring should be pursued up to 24 months of treatment.

Original Article

Background and purpose

Asymptomatic intracranial hemorrhage (aICH) is a common occurrence after endovascular treatment (EVT) for acute ischemic stroke (AIS). The aims of this study were to address its impact on 3‐month functional outcome and to identify risk factors for aICH after EVT.

Methods

Patients with AIS attributable to anterior circulation large vessel occlusion who underwent EVT were enrolled in a multicenter prospective registry. Based on imaging performed 22–36 h post‐EVT, we included patients with no intracranial hemorrhage (ICH) or aICH. Poor outcome defined as a 3‐month modified Rankin Scale (mRS) score 4–6 and overall 3‐month mRS score distribution were compared according to presence/absence of aICH, and aICH subtype using logistic regression. We assessed the risk factors of aICH using a multivariate logistic regression model.

Results

Of the 1526 patients included in the study, 653 (42.7%) had aICH. Patients with aICH had a higher rate of poor outcome: odds ratio (OR) 1.88 (95% confidence interval [CI] 1.44–2.44). Shift analysis of mRS score found a fully adjusted OR of 1.79 (95% CI 1.47–2.18). Hemorrhagic infarction (OR 1.63 [95% CI 1.22–2.18]) and parenchymal hematoma (OR 2.99 [95% CI 1.77–5.02]) were associated with higher risk of poor outcome. Male sex, diabetes, coronary artery disease, baseline National Institutes of Health Stroke Scale score and Alberta Stroke Program Early Computed Tomography Score, number of passes and onset to groin puncture time were independently associated with aICH.

Conclusions

Patients with aICH, irrespective of the radiological pattern, have a worse functional outcome at 3 months compared with those without ICH after EVT for AIS. The number of EVT passes and the time from onset to groin puncture are factors that could be modified to reduce deleterious ICH.

Original Article

Background and purpose

Changes of brain structure and function have been described in peripheral neuropathies. The aim of our study was to systematically investigate possible modifications of major large‐scale brain networks using resting‐state functional magnetic resonance imaging (RS‐fMRI) in Charcot–Marie–Tooth disease type 1A (CMT1A) patients.

Methods

In this cross‐sectional study, 3‐T MRI brain scans were acquired of right‐handed genetically confirmed CMT1A patients and age‐ and sex‐comparable healthy controls. Patients also underwent clinical and electrophysiological examinations assessing neurological impairment. RS‐fMRI data were analysed using a seed‐based approach, with 32 different seeds sampling the main hubs of default mode, sensorimotor, visual, salience (SN), dorsal attention, frontoparietal, language and cerebellar networks. Between‐group differences in terms of functional connectivity (FC) with the explored seeds were tested voxelwise, correcting for local grey matter density to account for possible structural abnormalities, whilst the relationship between FC modifications and neurological impairment was investigated using robust correlation analyses.

Results

Eighteen CMT1A patients (34.0 ± 11.4 years; M/F 11/7) were enrolled, along with 20 healthy controls (30.1 ± 10.2 years; M/F 11/9). In the CMT group compared to controls, clusters of increased FC with the visual cortex ( = 0.001), SN ( < 6 × 10), dorsal attention network ( < 8 × 10) and language network ( < 7 × 10) were found, along with a single cluster of reduced FC with the visual cortex in the left lentiform nucleus ( = 10). A significant correlation emerged between neurophysiological impairment and increased FC with right temporal language areas ( = 0.655,  = 0.006), along with an association between walking ability and increased FC with the left supramarginal gyrus (SN) ( = 0.620,  = 0.006).

Conclusions

Our data show evidence of diffuse functional reorganization involving multiple large‐scale networks in the CMT1A brain, independent of structural modifications and partially correlating with peripheral nerve damage and functional impairment.

Letters to the Editor

Response to: SARS‐CoV‐2 associated Guillain‐Barré syndrome in 62 patients

Letters To The Editor

SARS‐CoV‐2–associated Guillain‐Barre syndrome in 62 patients

Short Communication

Background and purpose

Gender bias is a known issue in healthcare and academia. We analysed the gender of patients reported in the literature with ‘man‐in‐the‐barrel’ syndrome or equivalent semiological terms.

Methods

A search in the PubMed database was conducted using the terms ‘man‐in‐the‐barrel’, ‘person‐in‐the‐barrel’, ‘woman‐in‐the‐barrel’, ‘brachial diplegia’, ‘flail arm’ and ‘cruciate paralysis’. All articles published between 1969 and 2020 containing a detailed description compatible with the original description of man‐in‐the‐barrel syndrome were included.

Results

Ninety‐five patients with a clinical picture compatible with man‐in‐the‐barrel syndrome were included. Up to 33% of patients were female. Overall, the proportion of female patients with man‐in‐the‐barrel syndrome was 25%.

Discussion and conclusions

The term man‐in‐the‐barrel may disenfranchise up to a third of women presenting with brachial diplegia with undesirable consequences. We propose a gender‐neutral alternative such as ‘person‐in‐the‐barrel’.

Short Communication

Background and purpose

When switching between monoamine oxidase type B (MAO‐B) inhibitors, a 15‐day suspension period is a precautionary measure to avoid a serotonin syndrome and hypertensive crisis. However, this indication results in a major inconvenience for parkinsonian patients because of the worsening of their clinical condition. In routine clinical practice, neurologists often perform a substitution of these two drugs without solution of continuity (i.e. overnight), to avoid worsening of fluctuations and prolonged OFF periods. Therefore, a safety open label study was performed to investigate the possible risks of switching overnight from rasagiline to safinamide.

Methods

The study population included 20 advanced patients with Parkinson's disease on stable treatment with rasagiline and levodopa (alone or in combination with other anti‐parkinsonian medication). The possible occurrence of serotonin syndrome and hypertension was monitored through a strict clinical observation and a 24‐h Holter recording (ABPM) performed twice, whilst subjects were on rasagiline and immediately after switching to safinamide.

Results

No cases of serotonin syndrome or hypertensive crisis occurred during the study. Changes that were not significant occurred in the primary end‐point: 24‐h mean blood pressure (BP) had a mild +4.4% increase in the ABPM2 versus ABPM1 ( = 0.17), 24‐h systolic and diastolic BP values were slightly higher at ABPM2 compared to ABPM1 (respectively +3.3%,  = 0.13; and 5.4%,  = 0.08) and 24‐h systolic BP variability was unchanged between the two ABPM evaluations (from 8.6 ± 2.9 to 8.9 ± 1.8;  = 0.27).

Conclusion

The results of the present study confirm that the overnight switch from rasagiline to safinamide is safe and well tolerated by patients.

Editorial

TEE, too hard to swallow?

Case Study

Abstract

COVID‐19 can occasionally be associated with cranial nerve involvement, but facial palsy, particularly if bilateral, is exceptional. We here report a patient who presented with severe bilateral facial palsy and evidence of SARS‐CoV‐2 infection preceded by upper respiratory symptoms. He also had serological evidence of coinfection with Epstein‐Barr virus, which could have also played a role in his neurological manifestations. PCR in the cerebrospinal fluid was negative for both EBV and SARS‐CoV‐2, which suggests an indirect, immune‐mediated mechanism rather than direct, viral‐induced damage. The patient was treated with prednisone 60 mg/24h with a tapering schedule and had a favorable outcome, with an almost complete recovery in 3 weeks. SARS‐CoV‐2 adds to the list of infectious agents causative of bilateral facial palsy. Coinfection with SARS‐CoV‐2 is not rare and should be considered in the differential diagnosis.

Editorial

Neither asymptomatic nor inevitable: intracerebral hemorrhage after reperfusion treatment

Editorial

Uncovering the stroke cause of the cryptogenic stroke subtype—embolic stroke of unknown source

Short Communication

Background and purpose

Posterior cortical atrophy (PCA) is a rare neurodegenerative syndrome, defined by a distinctive clinical‐radiological profile, with Alzheimer's disease (AD) pathology accounting for the majority of cases. The aim of this report was to present the case of a patient with impairment of visual and constructional abilities as initial manifestations.

Method

The patient underwent a multidimensional assessment, including neuropsychological evaluation, structural and functional imaging and genetic screening.

Results

Neurological and neuropsychological assessment showed an impairment of constructive and visuo‐spatial skills, associated with dyscalculia, simultanagnosia, optic ataxia and oculomotor apraxia. In accordance with the latest consensus criteria, a diagnosis of PCA was made. Consistent with the clinical findings, structural and functional imaging showed a peculiar pattern of atrophy with primary involvement of right parieto‐occipital cortices, whereas cerebrospinal fluid biochemical analysis did not reveal a profile compatible with AD pathology. Genetic screening identified a known pathogenic mutation.

Conclusion

We present a case of PCA in a mutation carrier in whom a concomitant AD pathological process was excluded. Consequently, although lacking histological data, our case suggests ‐related pathology causative of PCA. Through this report we provide further evidence for a new neurodegenerative pathway leading to PCA, extending the clinical spectrum of ‐associated phenotypes.